Status:
RECRUITING
The Ketogenic Diet for Alzheimer's Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
France Alzheimer
Conditions:
Alzheimer Disease, Early Onset
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The ketogenic diet (KD) is a metabolic shift, which stimulates the liver oxidation of fatty acids to produce ketone bodies. These ketone bodies represent an alternative fuel source for the brain. The ...
Detailed Description
Research context: Alongside the amyloid plaques and neurofibrillary tangles, the neuroinflammation triggered by the central nervous system's innate immune response plays a central role in the pathoge...
Eligibility Criteria
Inclusion
- Age \>= 50
- AD confirmed by biomarkers (CSF and/or PET scan)
- CDR score=0.5 or 1
- Speaking/understanding French
- Presence of a caregiver
Exclusion
- Diabetes
- Other neurological disease
- Chronic inflammatory disease or anti-inflammatory medication (e.g. NSAI, corticosteroids)
- Uncontrolled dyslipidemia
- Malnutrition (BMI \< 18; or weight loss \> 5% in 1 month or 10% in 6 months; or MNA \< 17)
- Severe chronic condition or organ dysfunction
Key Trial Info
Start Date :
March 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04701957
Start Date
March 30 2023
End Date
March 1 2027
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cognitive Neurology Center - Lariboisière Fernand Widal University Hospital (APHP)
Paris, France, 75010